Vivos Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Vivos Therapeutics

27/03/2023 13:53

* Vivos Therapeutics Inc  VVOS.OQ   VVOS.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 29
(estimated). 
    * The Littleton Colorado-based  company is expected to
report  a
3.6% increase in revenue to $4.551 million from $4.39 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vivos Therapeutics
Inc is
for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "Buy".​
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $2.38​, above​ its last closing price
of $0.34. ​​​

This summary was machine generated March 27 at 12:53 GMT.  All
figures in US dollars  unless otherwise stated